Application Notes: Procainamide is a common antiarrhythmic agent used to treat cardiac arrhythmias. According to USP methods procainamide hydrochloride contains not less than 98% and no more than 102% procainamide based on the dried basis. The USP HPLC method for the separation of procainamide and 4-aminobenzoic was developed on Legacy L1 column according to the US Pharmacopeia methodology. L1 classification is assigned to reversed-phase HPLC column containing C18 ligand. Support for the material is spherical silica gel with particles size 3-10 um and pore size of 100-120A. Resolution between critical pairs corresponds to rules and specifications of UPS.
Reference: USP 35- NF30
Column | Legacy L1, 4.6×150 mm, 5 µm, 100A |
Mobile Phase | MeOH/H2O – 60/40% |
Buffer | TEAPh pH 7.5 |
Flow Rate | 1.0 ml/min |
Detection | UV, 270 nm |
Class of Compounds |
Drug, Antiarrhythmic, Hydrophobic, Ionizable |
Analyzing Compounds | Procainamide, 4-Aminobenzoic acid |
Application Column
Legacy L1
SIELC's family of Legacy columns is based on the United States Pharmacopeia's (USP) published chromatographic methods and procedures. Numerous brands have columns used in USP reference standards and methods. USP has created various designations to group together columns with similar types of packing and properties in the solid phase. SIELC's Legacy columns adhere to these strict requirements and properties, allowing you to easily replace older columns that are no longer available without needing to significantly modify your method or SOPs.
Select optionsProcainamide